Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 3/20 | 0.55 |
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 12/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11213612 | 0.86 | FFAR1 (0.61) | PPARDPPARAPPARGFFAR1CYP2C19 | |
| SCHEMBL11442482 | 0.86 | FFAR1 (0.55) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL11440770 | 0.83 | FFAR1 (0.52) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL11436050 | 0.83 | FFAR1 (0.52) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL7994920 | 0.83 | MRGPRX4 (0.47) | MRGPRX4CYP2C19 | |
| SCHEMBL7980906 | 0.82 | FBP1 (0.57) | PPARDPPARAPPARGPTGDR2MRGPRX4 | |
| SCHEMBL15635194 | 0.81 | FFAR1 (0.53) | PPARDPPARAPPARGMRGPRX4FFAR1 | |
| SCHEMBL1045484 | 0.81 | PPARA (0.55) | PPARDPPARAPPARGPTGDR2CYP2C19 | |
| SCHEMBL581884 | 0.81 | PPARA (0.59) | PPARDPPARAPPARGPTGDR2MRGPRX4 | |
| SCHEMBL31153061 | 0.80 | PPARD (0.70) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | PPARD 241/4885PPARA 455/4885PPARG 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.